Skip to main content

Table 1 Baseline and clinical characteristics of patients and their correlation with grade ≥ 2 acute radiation pneumonitis

From: Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients

Characteristics

No. of Patients

(N = 183) (%)

No. of Grade ≥ 2 RP

(N = 26) (%)

Odds Ratio

95% CI

P Value*

Age

 ≤ 63 (Median)

98 (53.6)

13(50.0)

Reference

  

 > 63 (Median)

84(45.9)

13(50.0)

1.21

0.53–2.78

0.651

Gender

 Male

162(88.5)

20(76.9)

Reference

  

 Female

21(11.5)

6(23.1)

2.84

0.99–8.17

0.053

Smoking

 Never

42(23.0)

7(26.9)

Reference

 

0.644

 Current

77(42.1)

12(46.2)

0.92

0.33–2.56

0.878

 Former

64(35.0)

7 (26.9)

0.61

0.20–1.90

0.397

Pathology

 Squamous

112(61.7)

19 (73.1)

Reference

 

0.570

 Adenocarcinoma

30(16.4)

3(11.5)

0.54

0.15–1.98

0.355

 Small Cell

35(19.7)

3(11.5)

0.46

0.13–1.65

0.234

 Others

6(2.2)

1(3.8)

0.98

0.11–8.86

0.985

Stage

 I/II

14(7.7)

0(0)

0.00

 

0.999

 III

115(62.8)

20 (76.9)

Reference

 

0.578

 IV

54(29.5)

6 (23.1)

0.59

0.22–1.58

0.295

Chemo

 No

25(13.7)

1(3.8)

Reference

  

 Yes

158(86.3)

25(96.2)

4.51

0.58–34.89

0.149

Surgery

 No

139(76)

20(76.9)

Reference

  

 Yes

44(24)

6(23.1)

0.94

0.35–2.51

0.901

PGTV Volume

 ≤ 135.1 (Median)

92(50)

13(50)

Reference

  

 > 135.1 (Median)

91(50)

13(50)

1.0

0.44–2.32

0.976

PTV Volume

 ≤ 543.6 (Median)

92(50)

17(65)

Reference

  

 > 543.6 (Median)

91(50)

9(35)

0.48

0.20–1.15

0.101

PGTV prescription

 ≤ 54 (Median)

113(62)

14(54)

Reference

  

 > 54 (Median)

70(38)

12(46)

1.46

0.63–3.38

0.373

PTV prescription

 ≤ 50 (Median)

161(88)

23(88)

Reference

  

 > 50 (Median)

22(12)

3(12)

0.95

0.26–3.46

0.935

  1. Abbreviation: PTV planning target volume, PGTV planning gross tumor volume, V5/20 volume of lung receiving a dose ≥5/20 Gy, MLD mean lung dose
  2. *By repeated analysis of variance test (ANOVA)